69 related articles for article (PubMed ID: 38482432)
1. Corrigendum: Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma.
Chi H; Peng G; Yang J; Zhang J; Song G; Xie X; Strohmer DF; Lai G; Zhao S; Wang R; Yang F; Tian G
Front Endocrinol (Lausanne); 2024; 15():1421538. PubMed ID: 38784067
[TBL] [Abstract][Full Text] [Related]
2. A centrosome-related gene signature for predicting the overall survival of uveal melanoma.
Yu X; Guo X; Li W; Li J
Transl Cancer Res; 2024 Feb; 13(2):771-781. PubMed ID: 38482432
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data.
Wang W; Zhao H; Wang S
Front Immunol; 2023; 14():1099071. PubMed ID: 36793711
[TBL] [Abstract][Full Text] [Related]
4. Identification of Survival-Related Metabolic Genes and a Novel Gene Signature Predicting the Overall Survival for Patients with Uveal Melanoma.
Guo X; Yu X; Li F; Xia Q; Ren H; Chen Z; Xing Y
Ophthalmic Res; 2022; 65(5):516-528. PubMed ID: 35390784
[TBL] [Abstract][Full Text] [Related]
5. Construction of oxidative phosphorylation-related prognostic risk score model in uveal melanoma.
Zhan Z; Lin K; Wang T
BMC Ophthalmol; 2024 May; 24(1):204. PubMed ID: 38698303
[TBL] [Abstract][Full Text] [Related]
6. Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma.
Chi H; Peng G; Yang J; Zhang J; Song G; Xie X; Strohmer DF; Lai G; Zhao S; Wang R; Yang F; Tian G
Front Endocrinol (Lausanne); 2022; 13():1056310. PubMed ID: 36568076
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics.
Yu X; Li W; Feng Y; Gao Z; Wu Q; Xia Y
Sci Rep; 2023 Apr; 13(1):6241. PubMed ID: 37069207
[TBL] [Abstract][Full Text] [Related]
8. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Howlett S; Carter TJ; Shaw HM; Nathan PD
Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
[TBL] [Abstract][Full Text] [Related]
9. A Novel Glycolysis-Related Signature for Predicting the Prognosis and Immune Infiltration of Uveal Melanoma.
Guo X; Yu X; Zhang Y; Luo H; Huang R; Zeng Y; Duan C; Chen C
Ophthalmic Res; 2023; 66(1):692-705. PubMed ID: 36858025
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
Piperno-Neumann S; Carlino MS; Boni V; Loirat D; Speetjens FM; Park JJ; Calvo E; Carvajal RD; Nyakas M; Gonzalez-Maffe J; Zhu X; Shirley MD; Ramkumar T; Fessehatsion A; Burks HE; Yerramilli-Rao P; Kapiteijn E
Br J Cancer; 2023 Apr; 128(6):1040-1051. PubMed ID: 36624219
[TBL] [Abstract][Full Text] [Related]
11. Advances in the clinical management of uveal melanoma.
Carvajal RD; Sacco JJ; Jager MJ; Eschelman DJ; Olofsson Bagge R; Harbour JW; Chieng ND; Patel SP; Joshua AM; Piperno-Neumann S
Nat Rev Clin Oncol; 2023 Feb; 20(2):99-115. PubMed ID: 36600005
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
